Which Country Is Jemperli (Dostarlimab) Cheapest In? — 2026 Guide

Why does the price differ so much between countries?

Jemperli (dostarlimab) is a humanised PD-1 immune checkpoint inhibitor developed by GSK, approved for mismatch-repair-deficient (dMMR) or microsatellite-instability-high (MSI-H) recurrent or advanced endometrial cancer, and for other dMMR solid tumours, typically after prior treatment has failed. It is supplied as a concentrate for intravenous infusion, given every three or six weeks depending on the dosing schedule and stage of treatment. Because it is administered in a hospital oncology day unit rather than dispensed at a retail pharmacy counter, Jemperli moves through institutional procurement channels — hospital tenders and negotiated framework contracts — and that channel is what drives most of the cross-country variation in published prices.

Within the PD-1/PD-L1 checkpoint-inhibitor class, Jemperli competes with better-established agents used across a wide range of tumour types, and its comparatively narrow, biomarker-defined dMMR/MSI-H indication shapes how national bodies weigh its cost-effectiveness against broader-label competitors. In Türkiye, TİTCK applies external reference pricing to biologics like Jemperli just as it does to oral oncology products: the published price tracks the lowest ex-factory price found across a defined basket of EU reference countries, converted using the fixed "pharmaceutical euro" (Dönemsel Avro Değeri) rather than the live market rate, as published on the TİTCK price list and gazetted in the Resmî Gazete.

Germany evaluates Jemperli under its AMNOG early-benefit-assessment framework, with free pricing permitted for the first months after launch followed by a negotiated price backdated to month seven. NICE in England applies its cost-per-QALY threshold, raised from the long-standing £20,000–£30,000 range to £25,000–£35,000, announced 1 December 2025 and effective from April 2026 (see NICE), with the EMA's assessment underpinning the biomarker-restricted indication used across Europe (EMA). The United States has no equivalent government reference mechanism, part of why the RAND Corporation's international price comparison found gross US list prices averaging far above prices in other high-income countries across all drugs.

Because Jemperli is hospital-administered, most institutions never pay the published reference price: they procure through tenders and confidential discount agreements not disclosed publicly, and biomarker testing pathways (mismatch-repair or microsatellite-instability testing) that gate eligibility also vary by health system. Every published comparison, including this one, should therefore be read as a comparison of list prices rather than what any hospital or patient actually pays. For the underlying mechanics of Türkiye's published prices, see our explainer on why medicines cost less in Türkiye.

How is the price set in each country?

The table below compares pricing systems, not prices. Each country publishes — or does not publish — its own official list, and that published list is the only figure worth relying on. Follow the link in the last column and read the current entry yourself.

How can I obtain a medicine legally from a lower-price market?

There is a lawful route in most countries, and it starts in the same place everywhere: a valid prescription in your own name, issued by the physician treating you. What differs is the import permit. The procedures below are stated only where they could be verified at the national authority.

United Arab Emirates. MOHAP operates a permit to import medicines for personal use through its Electronic Drug Establishment service. The permit is free and is issued within 3 working days. You log in with a MOHAP account or UAE Pass.

Saudi Arabia. Applications run through the SFDA Controlled Drugs System at cds.sfda.gov.sa, under a guideline published on 14 August 2025. Read the current SFDA regulations page before you travel — the requirements are revised periodically.

Qatar. For non-controlled medicines there is no pre-approval: you may carry up to a 60-day supply through the Green Channel, in the original packaging, with a copy of the prescription and a signed, stamped letter from your doctor. For controlled medicines you need advance approval and must use the Red Channel; supporting documents must be no older than 6 months and in Arabic or English.

Kuwait and Azerbaijan. Confirm the current procedure directly with the national authority before shipping or travelling — Kuwait Ministry of Health and Azerbaijan Tariff Council. We do not publish a step list for these two countries because the procedure could not be verified at source.

1. United Arab Emirates — obtain a prescription in the applicant's own name, issued within the last 3 months.
2. Obtain a medical report from the treating facility, authenticated by the health authority and issued within the last year.
3. Prepare an Emirates ID or passport copy for the applicant.
4. Log in to the MOHAP service with a MOHAP account or UAE Pass and submit the personal-import application.
5. Keep the quantity within the limit: no more than a 1-month supply for controlled medicines, and no more than a 3-month supply for non-controlled medicines.
6. Wait for the decision — the service is free and normally issued within 3 working days.
7. Contact MOHAP on 800 111 11 or at import.export@mohap.gov.ae if the application stalls.

What is named patient supply?

Named patient supply is the international concept behind almost every lawful cross-border medicine route. The clearest codified example is the United Kingdom's MHRA Guidance Note 14, built on Regulation 167 of the Human Medicines Regulations 2012.

Four conditions define it: the order must be unsolicited; the product must be specified by the prescriber; the prescriber must be directly responsible for the patient; and there must be a genuine special clinical need that no authorised product meets.

The honesty point matters here: the European Court has held that "financial considerations cannot, in themselves" establish a special clinical need. A lower price in another country is not, by itself, a lawful basis for a named-patient import. The lawful bases are clinical.

Is the Jemperli I'm being offered genuine?

No falsified batches of Jemperli have been recorded in WHO's alert series to date. That absence is not proof that any individual pack you are offered is genuine — it only means there is no documented incident to cite, and any hospital-infused biologic sourced outside licensed distribution channels still carries some risk that should be actively checked, not assumed away.

Because Jemperli is a single-use vial administered as an infusion under direct oncology supervision, verification depends on hospital pharmacy staff checking the outer carton, the vial label, the batch number and the appearance of the solution before it is diluted and infused — a falsified or mishandled vial reaching the infusion chair has usually already passed several checkpoints where it could have been caught.

• Scan the carton's GS1 DataMatrix and confirm it decodes to AI 01 (GTIN), AI 21 (serial number), AI 17 (expiry) and AI 10 (batch) matching the vial label exactly.
• If sourced in Türkiye, verify the karekod is registered on the national İlaç Takip Sistemi (İTS) track-and-trace system at its.saglik.gov.tr before administration.
• Ask for a continuous, unbroken 2–8°C temperature log covering the actual shipment you are receiving, not a generic cold-chain certificate — Jemperli must never be frozen or shaken.
• Before infusion, visually inspect the vial and diluted solution for particulate matter or discolouration, and check that the vial seal and label are intact and undamaged.
• Confirm the carton has not been opened and re-closed, and that the vial's tamper-evident seal shows no sign of having been broken and replaced.
• Confirm that dMMR or MSI-H biomarker testing was documented before treatment was authorised, since eligibility testing is itself a marker of a licensed oncology service following the approved protocol.
• Cross-check any batch you are uncertain about against our WHO falsified medicine alerts tracker and review our guide to checking that a medicine is genuine before the dose is administered.

Frequently asked questions

Sources

• Resmî Gazete — Beşeri Tıbbi Ürünlerin Fiyatlandırılmasına Dair Karar No. 11031 — retrieved: 2026-07-28
• TİTCK — published medicine price list — retrieved: 2026-07-28
• MOHAP (UAE) — import medicine for personal use — retrieved: 2026-07-28
• SFDA (Saudi Arabia) — regulations — retrieved: 2026-07-28
• SFDA Controlled Drugs System — retrieved: 2026-07-28
• Qatar MOPH — drug prices — retrieved: 2026-07-28
• Kuwait Ministry of Health — retrieved: 2026-07-28
• Azerbaijan Tariff Council (Tarif Şurası) — retrieved: 2026-07-28
• NICE (United Kingdom) — retrieved: 2026-07-28
• G-BA (Germany) — AMNOG benefit assessment — retrieved: 2026-07-28
• RAND — International prescription drug price comparisons (published 1 Feb 2024) — retrieved: 2026-07-28
• Frontiers in Pharmacology — European hospital price transparency study (9 Mar 2026) — retrieved: 2026-07-28
• MHRA Guidance Note 14 — supply of unlicensed medicinal products — retrieved: 2026-07-28

Country availability pages for this medicine

Related pages

Immune checkpoint inhibitors

Related high-cost medicines